Immunomedics

Immunomedics, Inc. was an American biotechnology company focused on cancer therapies, particularly antibody-drug conjugates (ADCs). Based in Morris Plains, New Jersey, the company was founded in 1982 and developed proprietary ADC platforms that attach cytotoxic agents to antibodies targeting tumor-associated antigens, such as Trop-2.

The firm’s lead product candidate was sacituzumab govitecan (formerly IMMU-132), an ADC targeting Trop-2 and linked to SN-38, a topoisomerase I inhibitor. Sacituzumab govitecan was designed to treat Trop-2–positive cancers and progressed through clinical development for several indications. In addition to sacituzumab govitecan, Immunomedics pursued multiple other ADC programs in its pipeline.

In 2020, Gilead Sciences announced an agreement to acquire Immunomedics for approximately $21 billion, and the acquisition was completed later that year, integrating Immunomedics’ assets into Gilead’s oncology portfolio. Sacituzumab govitecan, marketed under the brand Trodelvy, became a central product within that portfolio and achieved additional regulatory approvals for expanded indications.

The acquisition illustrated growing investor interest in antibody-drug conjugate technology and Trop-2–targeted therapies. Immunomedics’ work contributed to the development of ADC strategies against solid tumors and influenced subsequent approaches in cancer therapeutics, with Trodelvy representing a notable example of an ADC entering multiple clinical indications.